Phosphodiesterase 5 Inhibitors for Erectile Dysfunction

1. NIH Consensus Conference. Impotence: NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.

2. Korenman SG . Epidemiology of erectile dysfunction. Endocrine 2004; 23: 87–91.

3. Feldman HA , Goldstein I , Hatzichristou DG , Krane RJ , McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

4. Siegel T , Moul JW , Spevak M , Alvord WG , Costabile RA . The development of erectile dysfunction in men treated for prostate cancer. J Urol 2001; 165: 430–5.

5. Stock RG , Kao J , Stone NN . Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001; 165: 436–9.

6. Feldman HA , Johannes CB , Derby CA , Kleinman KP , Mohr BA , Araujo AB , McKinlay JB . Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med 2000; 30: 328–38.

7. Goldstein I . The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am J Cardiol 2000; 86: 41F–5F.

8. Kandeel FR , Koussa VK , Swerdloff RS . Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocr Rev 2001; 22: 342–88.

9. Gresser U , Gleiter CH . Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature. Eur J Med Res 2002; 7: 435–46.

10. Finger WW , Lund M , Slagle MA . Medications that may contribute to sexual disorders. A guide to assessment and treatment in family practice. J Fam Pract 1997; 44: 33–43.

11. Brock GB , Lue TF . Drug-induced male sexual dysfunction: an update. Drug Saf 1993; 8: 414–26.

12. Bansal S . Sexual dysfunction in hypertensive men: a critical review of the literature. Hypertension 1988; 12: 1–10.

13. Burnham TH , Wickersham RM , Novak KK , eds. Drug facts and comparisons. St. Louis, MO: Facts and Comparisons, 2004.

14. Prisant LM , Carr AA , Bottini PB , Solursh DS , Solursh LP . Sexual dysfunction with antihypertensive drugs. Arch Intern Med 1994; 154: 730–6.

15. Barksdale JD , Gardner SF . The impact of first-line antihypertensive drugs on erectile dysfunction. Pharmacotherapy 1999; 19: 573–81.

16. Mitchell JE , Popkin MK . Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharmacol 1983; 3: 76–9.

17. Mitchell JE , Popkin MK . Antipsychotic drug therapy and sexual dysfunction in men. Am J Psychiatry 1982; 139: 633–7.

18. Clayton AH , Pradko JF , Croft HA , Montano CB , Leadbetter RA , Bolden-Watson C , Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357–366.

19. Fava M , Rankin M . Sexual functioning and SSRIs. J Clin Psychiatry 2002; 63 (suppl 5): 13–6.

20. Kennedy SH , McCann SM , Masellis M , McIntyre RS , Raskin J , McKay G , Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002; 63: 181–6.

21. Rosen RC , Kostis JB . Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92 (suppl): 9M–18M.

22. Crowe SM , Streetman DF . Vardenafil treatment for erectile dysfunction. Ann Pharmacother 2004; 38: 77–85. DOI 10.1345/aph.1D019

23. Boolell M , Allen MJ , Ballard SA , Gepi-Attee S , Muirhead GJ , Naylor AM , Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52.

24. Meuleman E . Review of tadalafil in the treatment of erectile dysfunction. Exp Opin Pharmacother 2003; 4: 2049–56.

25. Fazio L , Brock G . Erectile dysfunction: management update. CMAJ 2004; 170: 1429–37.

26. Carrier S . Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol 2003; 10 (suppl 1): 12–6.

27. Kalsi JS , Bahadur G , Muneer A , Ozturk O , Christopher N , Ralph DJ , Novel PDE5 inhibitors for the treatment of male erectile dysfunction. Reproductive Biomedicine Online 2003; 7: 456–61.

28. Viagra (sildenafil citrate) prescribing information. www/viagra.com/professional/pi/proPackInsert.asp (accessed 2004 May 26).

29. Levitra (vardenafil HCL) tablets: prescribing information. www.levitra.com (accessed 2004 May 26).

30. Cialis (tadalafil) prescribing information. www.cialis.com (accessed 2004 May 26).

31. Cheitlin MD , Hutter AM , Brindis RG , Ganz P , Kaul S , Russell ROJ , ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33: 273–82.

32. Keating GM , Scott LJ . Vardenafil: a review of its use in erectile dysfunction. Drugs 2003; 63: 2673–703.

33. Pomerol JM , Rabasseda X . Tadalafil, a further innovation in the treatment of sexual dysfunction. Drugs Today 2003; 39: 103–13.

34. Webb DJ , Muirhead GJ , Wulff M , JA Sutton JA , R. Levi R , Dinsmore WW . Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36: 25–31.

35. Setter SM , Baker DE , Campbell RK , Johnson SB . Sildenafil (Viagra) for the treatment of erectile dysfunction. Diabetes Educator 1999; 25: 79–89.

36. Rosen RC , McKenna KE . PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Annu Rev Sex Res 2002; 3: 36–88.

37. McDonald LJ , Murad F . Nitric oxide and cGMP signaling. Adv Pharmacol 1995; 34: 263–75.

38. Sussman DO . Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc 2004; 104 (suppl 4): S11–5.

39. Pollack CV , Gibler BW . 2000 ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a practical summary for emergency physicians. Ann Emerg Med 2001; 38: 229–40.

40. Rohde G , Wensing G , Unger S , Sachse R . The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, is minimally affected by coadministration with cimetidine or ranitidine (abstract). Pharmacotherapy 2001; 21: 1254.

41. Brock GB , McMahon CG , Chen KK . Costigan T , Shen W , Watkins V , Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332–6.

42. Streidle C , Feldman R , Letteiri J , Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction (abstract). Presented at: Annual Meeting of the American Geriatrics Society, Chicago, May 9–13, 2001.

43. Steidle C P , Feldman R , Lettieri J , Agarwal V , Segerson T . Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction (abstract). J Am Geriatr Soc 2001; 49: S103.

44. Pryor J . Vardenafil: update on clinical experience. Int J Impot Res 2002; 14 (suppl 1): S65–9.

45. Brindis RG , Kloner RA . Sildenafil in patients with cardiovascular disease. Am J Cardiol 2003; 92 (suppl): 26M–36M.

46. Kloner RA , Mitchell M , Emmick JT . Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003; 92 (suppl): 47M–57M.

47. Herschorn S . Cardiovascular safety of PDE5 inhibitors. Can J Urol 2003; 10 (suppl 1): 23–8.

48. Kloner RA , Mitchell M , Emmick JT . Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92 (suppl): 37M–46M.

49. Goldstein I , Lue TF , Padma-Nathan H , Rosen RC , Steers WD , Wicker PA . Oral sildenafil in the treatment of erectile dysfunction. New Eng J Med 1998; 338: 1397–404.

50. Padma-Nathan H , Steers WD , Wicker PA . Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998; 52: 375–9.

51. Fagelman E , Fagelman A , Shabsigh R . Efficacy, safety, and use of sildenafil in urologic practice. Urology 2001; 57: 141–4.

52. Lewis R , Bennett CJ , Borkon WD , Boykin WH , Althof SE , Stecher VJ et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology 2001; 57: 960–5.

53. Rendell MS , Rajfer J , Wicker PA , Smith MD . Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281: 421–6.

54. El-Sakka AI . Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol 2004; 46: 503–9. DOI 10.1016/j.eururo.2004.06.005

55. Porst H , Rosen R , Padma-Nathan H , Goldstein I , Giuliano F , Ulbrich E , The efficacy and tolerability of vardenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192–9.

56. Porst H , Young JM , Schmidt AC , Buvat J ; Vardenafil Study Group. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology 2003; 62: 519–23.

57. Potempa A , Ulbrich E , Bernard I , Beneke M ; Vardenafil Study Group. Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. European Urology 2004; 46: 73–9.

58. Hatzichristou D , Francesco F , Buvat J , Laferriere N , Bandel TJ , Porst H ; European Vardenafil Study Group. The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men. European Urology 2004; 45: 634–41.

59. Hellstrom WJG , Gittelman M , Karlin G , Segerson T , Thibonnier M , Taylor T , Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61 (suppl 1): 8–14.

60. Rosen RC , Padma-Nathan H , Shabsigh R , Saikali K , Watkins V , Pullman WE . Cialis (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (abstract). J Urol 2001; 165 (suppl): 224.

61. Brock GB , McMahon CG , Chen KK , Costigan T , Shen W , Watkins V , Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332–6.

62. Porst H , Padma-Nathan H , Giuliano F , Anglin G , Varanese L , Rosen R . Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62: 121–5.

63. Skoumal R , Chen J , Kula K , Breza J , Calomfirescu N , Basson BR , Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004; 46: 362–9.

64. Montorsi F , Verheyden B , Meuleman E , Junemann KP , Moncada I , Valiquette L , Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339–45.

65. Goldstein I , Young JM , Fischer J , Bangerter K , Segerson T , Taylor T ; Vardenafil Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777–83.

66. Saenz de Tejada I , Anglin C , Knight JR , Emmick JT . Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159–64.

67. Perimenis P , Markou S , Gyftopoulos K , Athanasopoulos A , Giannitsas K , Barbalias G . Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. Eur Urol 2002; 41: 387–91.

68. Safarinejad MR . Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications 2004; 8: 205–10.

69. Brock G , Taylor T , Seger M , for the Vardenafil PROSPECT Group. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy (abstract). Eur Urol 2002; 1: 52.

70. Raina R , Lakin MM , Agarwal A , Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 2003; 62: 110–5.

71. Raina R , Lakin MM , Agarwal A , Sharma R , Goyal KK , Montague DK , Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 2004; 63: 960–6.

72. Raina R , Lakin MM , Agarwal A , Mascha E , Montague DK , Klein E , Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology 2004; 63: 532–7.

73. Zagaja G P , Mhoon DA , Aikens JE , Brendler CB . Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000; 56: 631–4.

74. Zippe CD , Jhaveri FM , Klein EA , Kedia S , Pasqualotto FF , Kedia A , Role of Viagra after radical prostatectomy. Urology 2000; 55: 241–5.

75. Montorsi F , Nathan HP , McCullough A , Brock GB , Broderick G , Ahuja S , Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004; 172: 1036–41.